Brian Bender: Computational Probes for Orphan GPCR

The GPCR superfamily contains hundreds of receptors that cannot be experimentally studied because no usable chemical probe exists for them. Finding an endogenous agonist - when one is even known - is rarely sufficient: a large peptide or lipidated compound may activate a receptor in vivo but is useless as a cell-based tool. This gap is one of the defining bottlenecks in receptor pharmacology, and closing it one receptor at a time will take decades.

Brian Bender's work addresses this problem computationally. At UCSF, he develops structural models of GPCRs using sparse experimental data - combining restraints from X-ray crystallography, NMR, and electron paramagnetic resonance spectroscopy - and applies large-scale virtual docking to identify candidate chemical probes across the understudied GPCR landscape. His approach scales across the family rather than stopping at individual targets.

Bender trained at the bench before moving fully into computation, and that transition was not planned. A stalled labeling project on the NPY2 receptor during his PhD at Vanderbilt redirected his entire trajectory - and eventually revealed that the patterns connecting receptors across the GPCR family were more interesting than any single structure.

ABOUT THE GUEST

Bender is a postdoctoral fellow at UCSF working at the intersection of computational structural biology and receptor pharmacology. His research focuses on predicting GPCR structural ensembles from limited experimental data and using virtual docking to identify chemical probes for orphan and understudied receptors. He trained as a structural biologist at Vanderbilt University, working with X-ray crystallography, protein NMR, and electron paramagnetic resonance before transitioning to computation during his PhD work on the NPY2, NPY1, and ghrelin receptors. His fluency in both bench and computational languages shapes how he builds models and how he interprets the experimental data that constrains them.

SCIENTIFIC THEMES OF THE CONVERSATION

• Computational structural modeling of GPCRs from sparse and low-resolution experimental data
  

• Virtual docking as a strategy for pan-GPCR chemical probe discovery
  

• The orphan receptor problem - why endogenous agonists are not sufficient tool compounds
  

• Bench-to-computation transitions and what fluency in both languages enables
  

• Family-wide approaches to receptor pharmacology versus single-receptor studies
  

• Building scientific community at the early-career stage

KEY INSIGHTS FROM THE CONVERSATION

The probe gap is a biological bottleneck, not just a chemical one

Without a usable chemical probe, a GPCR cannot be studied pharmacologically in a cell-based setting. Even when an endogenous agonist is known, it may be a large peptide or lipidated compound that cannot be practically dosed in vitro. Bender's work targets this gap directly - arguing that de-orphanizing a receptor biochemically and making it experimentally tractable are two separate problems.

Virtual docking changes the scale equation

Individual bench approaches to identifying tool compounds can take months to years per receptor. Virtual docking screens compress that timeline significantly and can be applied across many receptors in parallel. Bender frames this not as a replacement for bench pharmacology but as the only realistic path to coverage across the full orphan GPCR landscape.

The failed experiment that built a career

Bender's NPY2 labeling project - designed to generate DEER spectroscopy distance restraints for conformational modeling - never yielded usable data. Rather than a setback, it became a forced pivot into computation at precisely the moment his modeling skills were becoming sufficient to carry a project independently. The stalled experiment was the origin point of the approach he now applies at family scale.

Bench experience as a modeling guardrail

Knowing what an EC50 means experimentally, or what a Bmax implies about receptor expression, changes how computational restraints are built and applied. Bender credits his time at the bench with preventing the kind of over-interpretation that models built purely from computational intuition can produce - a perspective that shapes how he translates collaborators' data into structural constraints.

The eureka of the whole family

Months of manually reading sequence alignment tables - before Bender could write the scripts to automate the analysis - produced an unexpected result: structural and sequence patterns connecting receptors across GPCR subfamilies that he had not been told to look for. That period of laborious, close-range data inspection became the conceptual foundation of his pan-GPCR approach, and the moment he understood that one receptor was not enough.

Connecting scientists is its own form of science

Bender's role co-chairing the Gordon Research Seminar on Molecular Pharmacology is not separate from his scientific work - it is continuous with it. He articulates that the lateral connections formed at early-career conferences, between people who will be colleagues for the next 20 years, are a different kind of scientific output but no less consequential for where the field goes next.

EPISODE TIMELINE

Timestamps generated with AI assistance and are approximate. They may vary slightly from the final edited version.

• 00:00 Introduction

• 01:31 From structural biology to GPCR computation - how the path began

• 05:47 Modeling GPCR conformational ensembles from sparse data

• 07:44 Origin moment - a lab notebook at age 8

• 11:53 The NPY2 labeling project that stalled - and the pivot it forced

• 17:22 From NPY2 to ghrelin - when one receptor becomes a family question

• 19:54 Joining UCSF and building the pan-GPCR docking pipeline

• 21:53 Co-chairing the Gordon Research Seminar on Molecular Pharmacology

• 47:42 Why orphan receptors need chemical probes, not just endogenous agonists

• 52:54 Bench fluency as a guard against over-interpreting computational models

• 58:16 Advice for early-career scientists on connecting with the field

• 01:02:48 Eureka moment - patterns across the whole receptor family, read by eye

SELECTED QUOTES

About Dr. Brian Bender

Dr. Bender completed his undergraduate studies at Colgate University in upstate New York with a degree in Biochemistry. Between undergraduate and graduate school Brian worked as a technician in an academic lab before moving to Nashville, TN for graduate work at Vanderbilt University where he joined the Department of Pharmacology.

Brain’s work there primarily focused on structure prediction of GPCRs from sparse experimental data. He then moved to the University of California in San Francisco to continue his training as a postdoctoral researcher where he used structural models of GPCRs to virtually screen large compound libraries with the goal of finding new chemical matter to probe understudied and orphan receptors.

Brian is involved in organizing the GRC/GRS Molecular Pharmacology meeting, which has been postponed to 2023. Brian is one of the organizers of the upcoming

Transatlantic ECI GPCR Symposium.

Dr. Brian Bender on the web

• LinkedIn

• Twitter

• ResearchGate

• Dr.GPCR Member

• Google Scholar

• Dr. GPCR Ecosystem